What 14 Years in Vet Med Taught This Pet Owner About Never Giving Up

If you work in veterinary medicine long enough, you start to notice a pattern. 

The cat with three legs. The dog who came in as a stray and somehow never left. The FIV- positive kitten that nobody at the shelter was sure about, the one that locked eyes with the wrong person at the right moment and that was that. The pets with the longest medical histories and the most complex care needs have a way of ending up in the homes of the people who understand exactly what they're signing up for. 

And they sign up anyway. Every single time. 

Kristyn Allen, who is currently a Senior IT Project Specialist at VCA, has worked in the veterinary field for 14 years. She is not a clinician, but she is something the profession produces in abundance: a person whose proximity to animal medicine has permanently recalibrated her capacity for commitment. When a big, fluffy, polydactyl shelter cat found wandering by a Good Samaritan caught her eye, it was love at first sight. She adopted him immediately. She named him Harry. 

Two months later, Harry tested positive for FIV. Kristyn didn't flinch.

What Loving a Hard Case Actually Looks Like 

Harry's medical record reads like a textbook on feline resilience. After the FIV diagnosis came a thoracotomy for a lung infection. Then an enucleation surgery. Then a cryptococcal fungal infection. Then chronic kidney disease. Then, found incidentally during a complicated post- surgical hospitalization, a grade 1 to 2 heart murmur heard for the very first time — the first sign of what would become a diagnosis of hypertrophic cardiomyopathy. 

Most people would have made different choices somewhere along that road. The profession knows this. It is why the hardest cases so often end up with veterinary people. Not because they don't see the difficulty clearly. They see it more clearly than anyone. They choose it anyway because they also see what's possible on the other side of it. 

For Kristyn, each new diagnosis wasn't a reason to recalibrate her commitment to Harry. It was a reason to get more informed, more proactive, and more creative about how to advocate for him. She built relationships with specialists. She scoured Facebook groups for data points. She had frank conversations with her cardiologist about emerging therapies. She asked questions that most pet owners don't know to ask because she had spent 14 years inside a profession that taught her how. 

That combination of deep love and clinical literacy is exactly what allowed her to be in the right place when veterinary cardiology history was being made. 

A Drug That Arrived Right on Time 

Felycin-CA1 (sirolimus delayed-release tablets), the first and only FDA conditionally approved medication indicated for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM). It works in the early window of the disease, before symptoms appear, before significant structural changes have taken hold, to help prevent and delay the thickening of the left ventricular wall that characterizes HCM. Studies show measurable improvement in heart wall measurements in cats receiving Felycin CA-1 compared to those who didn't. See this study for full details: Study here. For a condition that previously offered only symptom management, this is not a small development. It is a genuine turning point. 

Harry's HCM was caught early. His diagnosis was mild with only slight left ventricular thickening, no left atrial enlargement, no recommendation for heart medications at the time of diagnosis. He was, in the language of the drug's indication, exactly the subclinical patient Felycin-CA1 was designed for. 

Kristyn had already heard about Felycin CA-1 before it was available. She brought it up at Harry's first cardiology appointment. She asked to be on the list. When it became available in September 2025, she was ready. 

She described the moment she finally had it in her hands as making her a little choked up, and not just for Harry, but for what it represented. A feline-specific medication for a feline-specific disease. For someone who had spent her career watching the gap between canine and feline medicine, it felt like an arrival. 

Twenty-Six Weeks Later 

Harry has been on Felycin CA-1 for 26 weeks as of this writing. Within the first two weeks, Kristyn noticed more energy, more playfulness, and full-speed sprinting through the house. He is bossing his three brothers around. He has strong opinions about everything and communicates them at volume. His kidney values have shown slight improvement. He is, by every measure that matters, thriving. 

He is also something else: a data point. Before starting Felycin CA-1 , Kristyn searched every Facebook group she could find for evidence of an FIV-positive cat being treated for HCM with rapamycin. She found nothing. Not one example. So she decided Harry would be the example, the searchable breadcrumb for the next cat parent who typed the same desperate search into Google at midnight and needed to know it was possible. 

She posts their updates regularly. She connects with cat owners around the world who find her through those posts. She treats every share as an act of advocacy for the cats and the people who love them the way she loves Harry. 

This is what the veterinary profession looks like from the inside. Not just the clinical expertise. The commitment. The refusal to count a patient out because the case is hard or the odds are long or the road ahead is uncertain. 

The Ones Worth Fighting For 

Harry turned ten years post-FIV-diagnosis in January 2026. He has had more second chances than most cats get first ones. Every single one of them happened because someone in his corner understood what was possible and pushed toward it. 

Veterinary professionals do this every day. For their patients. For their clients. And quietly, without much fanfare, for the animals in their own homes, the ones nobody else would take, the ones that found them by accident, the ones that turned out to be the whole point. 

Harry is one of those cats. 

And because Kristyn was the kind of person who never stopped fighting for him, he got to be here for a drug that was worth fighting toward. 

That's the story of Felycin CA-1 . But it's also the story of what this profession does best. 

Felycin-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-604. See prescribing information for complete details regarding adverse events, warnings, and precautions. For more information on which of your feline patients may be candidates, consult a veterinary cardiologist. 

Prescribing Information below:

FELYCIN®-CA1 (sirolimus delayed-release tablets)
Cardiac drug for oral use in cats only.
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-604. It is a violation of federal law to use this product other than as directed in the labeling. For complete prescribing information, see full package insert. 

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. 

Indication: for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM). 

Dosage and Administration: Administer Felycin-CA1 at a target dose of 0.3 mg/kg orally once weekly. Tablets should be swallowed whole and not chewed. Do not split or crush tablets. Felycin- CA1 should be administered with a meal. Cats weighing less than 2.5 kg cannot be accurately dosed. 

Contraindications: Felycin-CA1 should not be used in cats with diabetes mellitus. Discontinue immediately if a cat receiving Felycin-CA1 is diagnosed with diabetes mellitus. The administration of Felycin-CA1 to a cat that developed diabetes mellitus was associated with the development of diabetic ketoacidosis and death. Do not administer in cats with pre-existing liver disease. 

User Safety Warnings: Not for human use. Keep out of reach of children. Contact a physician in case of accidental ingestion by humans. Pregnant and breastfeeding women
should avoid contact with Felycin-CA1. People with known hypersensitivity to sirolimus should administer Felycin-CA1 with caution. 

Animal Safety Warnings: Administration of Felycin-CA1 with drugs that inhibit cytochrome P-450
3A4 or P-glycoprotein, such as calcium channel blockers, amiodarone, azoles, or cyclosporine, may increase risk for toxicity. Use caution when administering in cats with the MDR1 mutation or when administering concomitantly with another P-gp substrate. Treatment with Felycin-CA1 could impact the cat’s ability to mount an adequate immune response to vaccinations. Concurrent administration of Felycin-CA1 did not impact the cat’s ability to mount an adequate immune response to a killed rabies vaccine. The impact of Felycin- CA1 for FHV-1, FCV, FPV, and FeLV has not been evaluated. Keep Felcyin-CA1 in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. 

Precautions: For use only in otherwise healthy cats with subclinical HCM in the absence of other causes of compensatory myocardial hypertrophy (e.g. systemic hypertension), current or   historic symptoms of congestive heart failure, arterial thromboembolism, and sever LV outflow tract obstruction. Treatment with Felycin-CA1 has been associated with the elevation of the transaminase enzymes, which include alanine aminotransferase (ALT) and aspartate aminotransferase (AST). The use of Felycin-CA1 in cats with viral disease like feline viral rhinotracheitis has not been evaluated. The safety and effectiveness of Felycin-CA1 has not been evaluated in cats with other cardiomyopathy phenotypes, in cats receiving beta blockers or corticosteroids, in cats with kidney disease, hyperthyroidism, or other significant systemic disease. The effectiveness of Felycin-CA1 has not been evaluated in sexually intact cats, therefore, should not be used in animals intended for breeding. 

Adverse Reactions: In a well-controlled pilot field study, 43 cats with subclinical HCM were administered either the label dose of Felycin-CA1 (0.3 mg/kg once weekly), twice the label dose (0.6 mg/kg once weekly), or a placebo control tablet and followed for 180 days or until removal from the study. The most frequently observed adverse reactions were cardiovascular in nature, relating to the progression of HCM, and included arrhythmia, congestive heart failure, syncope, and pericardial effusion. Other adverse reactions were lethargy, vomiting,
diarrhea, and inappetence. 

Clinical Pharmacology: Sirolimus is an immunosuppressant that targets and inhibits the mammalian target of rapamycin C1 (mTORC1) protein complex, a central regulator of cell growth and nutrient response. Studies in rodent models suggest mTOR inhibition by sirolimus attenuates cardiac hypertrophy by promoting autophagy, attenuating oxidative stress and blocking proinflammatory responses, thereby resulting in an improvement in cardiac function in rodents. 

Reasonable Expectation of Effectiveness: This product is conditionally approved by FDA pending a full demonstration of effectiveness. 

To obtain full product information for Felycin-CA1 please call 1-800-874- 9764. 

Manufactured for: PRN Pharmacal, Pensacola, FL 32514
PRN is a trademark of Pegasus Laboratories, Inc.

Dosage and Administration: For use in cats only. The total recommended dosage for Felycin-CA1 is 0.3 mg/kg once per week, dosed in conjunction with a meal. 

Storage: Store at 20-25°C (68-77°F). 

WARNINGS: NOT FOR USE IN HUMANS. KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN. 4-2025